E-GEOD-6400 - Transcription profiling of human A549 lung cancer cells treated with actinomycin D and sapphyrin PCI-2050 a new class of tumor-selective inhibitors of gene expression
Released on 26 October 2007, last updated on 23 June 2015
The goal of this project was to characterize changes in gene expression in response to the anti-cancer agent sapphyrin PCI-2050. Cultured A549 human lung cancer cells were treated with sapphyrin PCI-2050 or actinomycin D.
transcription profiling by array, co-expression, compound treatment, dose response
Synthesis and biologic properties of hydrophilic sapphyrins, a new class of tumor-selective inhibitors of gene expression. Zhong Wang, Philip S Lecane, Patricia Thiemann, Qing Fan, Cecilia Cortez, Xuan Ma, Danielle Tonev, Dale Miles, Louie Naumovski, Richard A Miller, Darren Magda, Dong-Gyu Cho, Jonathan L Sessler, Brian L Pike, Samantha M Yeligar, Mazen W Karaman, Joseph G Hacia.